Theravance Biopharma (TBPH) Non-Current Assets (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Non-Current Assets of $54.7 million for Q1 2026, down 71.72% year-over-year from $193.3 million in Q1 2025, and down 18.52% quarter-over-quarter from $67.1 million in Q4 2025.
Theravance Biopharma (TBPH) Non-Current Assets (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Non-Current Assets for 14 consecutive years, with $54.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 71.72% year-over-year to $54.7 million; the TTM figure through Mar 2026 stood at $242.3 million (down 72.11% YoY), while the FY2025 annual figure was $67.1 million, down 65.24% from the prior year.
- Non-Current Assets declined to $54.7 million in Q1 2026 per TBPH's latest filing, from $67.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $277.2 million in Q1 2023 and bottomed at $54.7 million in Q1 2026.
- Historically, Non-Current Assets has averaged $191.3 million across 5 years, with a median of $239.6 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 573.66% — and 2025, when it plunged 75.39%.
- Theravance Biopharma's Non-Current Assets stood at $253.9 million in 2022, then retreated by 2.16% to $248.5 million in 2023, then decreased by 22.28% to $193.1 million in 2024, then sank by 65.24% to $67.1 million in 2025, then slipped by 18.52% to $54.7 million in 2026.
- Business Quant data shows TBPH's Non-Current Assets at $54.7 million in Q1 2026, $67.1 million in Q4 2025, and $60.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 53.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.11 Mn |
| Mar 31, 2026 | 54.68 Mn |
| Dec 31, 2025 | 67.11 Mn |
| Sep 30, 2025 | 60.76 Mn |
| Jun 30, 2025 | 59.74 Mn |
| Mar 31, 2025 | 193.32 Mn |
| Dec 31, 2024 | 193.09 Mn |
| Sep 30, 2024 | 239.63 Mn |
| Jun 30, 2024 | 242.72 Mn |
| Mar 31, 2024 | 247.01 Mn |
| Dec 31, 2023 | 248.46 Mn |
| Sep 30, 2023 | 251.90 Mn |
| Jun 30, 2023 | 254.63 Mn |
| Mar 31, 2023 | 277.21 Mn |
| Dec 31, 2022 | 253.94 Mn |
| Sep 30, 2022 | 251.78 Mn |
| Jun 30, 2022 | 206.03 Mn |
| Mar 31, 2022 | 150.72 Mn |
| Dec 31, 2021 | 37.70 Mn |
| Sep 30, 2021 | 105.94 Mn |